‘Full fat’ sugary drinks such as colas increase the risk of obesity and are generally off-limits for diabetics.
Neoleukin to merge with Neurogene for $200m in cash reserves – Pharmaceutical Technology
The merger and financing rounds are expected to close in the last quarter of 2023, subject to appropriate approvals and securities filing with the US